MedTrace Logo

Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer

NCT03611179 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-08-02

No results posted yet for this study

Summary

Our study aims at assessment of response, survival and toxicity of frontline treatment with chemotherapy and Bevacizumab in patients having advanced epithelial ovarian cancer.

Conditions

  • Advanced Ovarian Cancer

Interventions

DRUG

Bevacizumab

The chemotherapy regimen will be Paclitaxel (175 mg/m2 of body surface area) administered intravenously over 3 h, followed by carboplatin (area under the curve 5) over 1 h, with standard antiemetic and hypersensitivity medications. In patients who develop dose-limiting peripheral neuropathy or hypersensitivity, paclitaxel will be replaced with docetaxel (75 mg/m2), which is administered intravenously over 1 h. Bevacizumab (15 mg/kg bodyweight) administered intravenously initially over 90 min (if tolerated, this time can be reduced to 60 min, and could be further reduced to a minimum of 30 min)

Sponsors & Collaborators

  • Assiut University

    collaborator OTHER

  • Nada Hassan Salah

    lead OTHER

Principal Investigators

  • mohammed A mekkawy, prof · Assiut University

  • mohammed A hassan, lecturer · Assiut University

  • hisham abo taleb, lecturer · Assiut University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-01
Primary Completion
2022-08-31
Completion
2022-09-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03611179 on ClinicalTrials.gov